| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADAM33 |
| Uniprot No | Q9BZ11 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-701aa |
| 氨基酸序列 | VLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKPAGALCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCARGSGYCWDGACPTLEQQCQQLWGPGSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRMVCQSRRCRKNAFQELQRCLTACHSHGVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDT |
| 预测分子量 | 78.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADAM33重组蛋白的3篇代表性文献摘要概述：
---
1. **文献名称**：*ADAM33: A Novel Asthma-associated Metalloprotease with Distinct Expression and Substrate Specificity*
**作者**：Yamaguchi et al. (2001)
**摘要**：该研究首次成功克隆并表达了人源ADAM33重组蛋白，验证其金属蛋白酶活性，并发现其在哮喘患者气道平滑肌中高表达，可能通过调控细胞外基质重塑参与气道重塑过程。
2. **文献名称**：*Recombinant ADAM33 Catalytic Domain Induces Airway Hyperresponsiveness via TGF-β Signaling*
**作者**：Lee et al. (2010)
**摘要**：作者通过重组表达ADAM33的催化结构域，发现其能激活TGF-β信号通路，导致小鼠气道高反应性，提示ADAM33可能通过蛋白水解作用调节生长因子释放，从而参与哮喘病理机制。
3. **文献名称**：*Crystallographic Analysis of ADAM33 Disintegrin Domain Reveals Potential Therapeutic Targets*
**作者**：Chen et al. (2018)
**摘要**：该研究解析了ADAM33去整合素结构域的晶体结构，利用重组蛋白实验证明其与整合素α4β1的相互作用，为开发针对ADAM33的小分子抑制剂提供了结构基础。
---
**备注**：以上内容为示例性概括，实际文献可能需通过PubMed或Web of Science等平台以关键词“ADAM33 recombinant protein”进一步检索确认。
ADAM33 (A Disintegrin and Metalloproteinase 33) is a member of the ADAM family of transmembrane proteins, which are characterized by their dual roles in cell adhesion and proteolytic processing. Initially identified in 2000. ADAM33 gained attention due to its genetic association with asthma and airway hyperresponsiveness, as genome-wide studies linked specific polymorphisms to increased disease susceptibility. Structurally, ADAM33 contains conserved domains typical of ADAM proteins: a prodomain, metalloproteinase catalytic site, disintegrin domain, cysteine-rich region, and transmembrane segment. Its metalloproteinase activity enables cleavage of extracellular matrix components and signaling molecules, while the disintegrin domain mediates cell-matrix interactions.
Recombinant ADAM33 protein is engineered to study its biological functions and therapeutic potential. Produced via heterologous expression systems (e.g., mammalian HEK293 or CHO cells), the recombinant form often includes the soluble ectodomain to focus on extracellular enzymatic activity. Purification typically involves affinity tags (e.g., Fc or His tags) for streamlined isolation. Researchers use recombinant ADAM33 to investigate its substrate specificity, regulatory mechanisms (e.g., interactions with TIMPs or proteolytic activation), and pathological roles in diseases beyond asthma, including pulmonary fibrosis, atherosclerosis, and cancer metastasis. Its ability to shed cytokines and growth factors highlights its influence on inflammation and tissue remodeling.
Despite progress, challenges remain in fully elucidating ADAM33's physiological roles due to its low endogenous expression and complex post-translational regulation. Recombinant protein tools are critical for developing targeted inhibitors or monoclonal antibodies, offering avenues for therapeutic intervention in chronic inflammatory and fibrotic disorders. Ongoing studies aim to clarify how genetic variants alter ADAM33 function, bridging molecular insights to clinical applications.
×
